No abstract available
Plain language summary
This Viewpoint discusses the US Food and Drug Administration’s authorization of marketing an at-home testing system for chlamydia and gonorrhea as a good first step in boosting access to screening and treatment and in reducing infection rates.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Chlamydia Infections* / diagnosis
-
Chlamydia trachomatis / isolation & purification
-
Female
-
Gonorrhea* / diagnosis
-
Health Services Accessibility
-
Humans
-
Male
-
Neisseria gonorrhoeae / isolation & purification
-
Self-Testing*
-
United States
-
United States Food and Drug Administration